Antibodies
11 January 2010
Facet Biotech Announces Enrollment of First Patient in Phase 2 Study of Elotuzumab in Patients With Relapsed Multiple Myeloma11 January 2010
Sorrento Therapeutics Announces Antibody Discovery and Development Alliance for the Prevention and Treatment of MRSA Infections11 January 2010
ABLYNX SUCCESSFULLY GENERATES NANOBODIES AGAINST AN ION CHANNEL AND ANNOUNCES NEW GPCR PROGRAMME11 January 2010
Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa Infections11 January 2010
FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis11 January 2010
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma11 January 2010
Trubion Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Study of SBI-087 for the Treatment of Rheumatoid Arthritis (RA)7 January 2010
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma7 January 2010
Tolerx Completes Enrollment in DEFEND-1, A Phase 3 Type 1 Diabetes Study With Otelixizumab6 January 2010
InNexus Biotechnology Develops New Psoriasis Product Based on Its Skin Permeating Antibody Technology4 January 2010
First Patient treated in BioInvent’s Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma4 January 2010
NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis29 December 2009
Pfizer Discontinues A Phase 3 Trial Of Figitumumab In Non-Small Cell Lung Cancer (NSCLC) For Futility24 December 2009
MedImmune Replies to FDA Complete Response Letter on Motavizumab22 December 2009
PDL BioPharma Announces New Licensing Agreement With Eli Lilly22 December 2009
Genentech Submits Supplemental Application to FDA for Lucentis in Patients with Retinal Vein Occlusion21 December 2009
UCB announces initial clinical trial results involving patients taking certolizumab pegol for moderate to severe Crohn’s disease21 December 2009
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline18 December 2009
Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union18 December 2009
Cangene receives a positive opinion from the European Medicines Agency (“EMA”) for Hepatitis B product18 December 2009
Thallion Announces Letter of Intent with LFB Biotechnologies to Develop and Commercialize Shigamabs®18 December 2009
Herceptin receives positive opinion in record time for the treatment of HER2-positive advanced stomach cancer in Europe17 December 2009
Adimab Announces New Antibody Discovery Collaborations and Achievement of Milestones in Two Existing Partnerships16 December 2009
ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports